Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

The RESTORE-IMI 1 phase 3 trial demonstrated the efficacy and safety of imipenem-cilastatin (IMI) combined with relebactam (REL) for treating imipenem-nonsusceptible infections. The objective of this analysis was to compare the outcomes among patients meeting eligibility requirements based on centra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Kaye, Keith S., Boucher, Helen W., Brown, Michelle L., Aggrey, Angela, Khan, Ireen, Joeng, Hee-Koung, Tipping, Robert W., Du, Jiejun, Young, Katherine, Butterton, Joan R., Paschke, Amanda
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2020
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7179630/
https://ncbi.nlm.nih.gov/pubmed/32094127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02203-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars